Lab Manager | Run Your Lab Like a Business

Product News

Sphere Fluidics Announces Enhanced Cyto-Mine Capability and Performance

Simplified design reduces manufacturing time and offers improved functionality to help streamline antibody discovery, cell line development, cell therapy, and synthetic biology workflows

Sphere Fluidics Cyto-Mine® System
  • Automated platform is now faster and easier to manufacture, commission, and service as a result of a simplified internal design
  • New electronics design improves system performance, reliability, and stability
  • Updated software features help to provide a better user experience, reduce user-instrument interaction, and allow for more robust data analysis
  • Enhanced capability and performance for the instrument enables users to access more functionality
Sphere Fluidics

CAMBRIDGE, UK — May 17, 2020 — Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, today announced it has enhanced the capability and performance of its Cyto-Mine® System. The simplified design offers improved functionality to help streamline workflows, reduce costs, increase throughput, and enable high-value clones to be captured in a single run.

Sphere Fluidics’ Cyto-Mine is an automated platform which integrates single cell screening, sorting, dispensing, imaging, and clone verification. It is now faster and easier to manufacture, commission, and service as a result of a simplified internal design. The new electronics design improves system performance, reliability, and stability, while the updated software features help to provide a better user experience, reduce user-instrument interaction, and allow for more robust data analysis. The enhanced capability and performance for the instrument enables users to access more functionality and the improved software offers a more advanced and reliable system to help further simplify antibody discovery, cell line development, cell therapy, and synthetic biology workflows. 

Dr. Marian Rehak, VP of research and development at Sphere Fluidics, said: “The new design is the culmination of 18 months' hard work by our R&D team. Due to the deployment of these latest improvements, researchers are now able to perform even faster selective screening of single cells to find rare lead candidates. Although, principally designed for antibody discovery and cell line development, the platform is very flexible and has now been demonstrated to be useful in a wide variety of application areas.”

Rob Treanor, operations director at Sphere Fluidics, said: “The new Cyto-Mine design not only unlocks increased functionality for scientists but is also faster to manufacture, commission, and service. A new user can learn how to run our user-friendly software within a single working day. We are helping our users to simplify their workflows with the added operational benefit of enhancing our service and support capacity.”

For further information about Sphere Fluidics Cyto-Mine, please visit: https://spherefluidics.com/products/cyto-mine/?v=79cba1185463 or watch the video: https://www.youtube.com/watch?v=N9XpZHvnzys&feature=emb_imp_woyt

Sphere Fluidics

The McClintock Building Suite 7, Ground Floor Granta Park Great Abington Cambridge CB21 6GP United Kingdom